000258264 001__ 258264
000258264 005__ 20250127124556.0
000258264 037__ $$aDZNE-2023-00610
000258264 1001_ $$0P:(DE-2719)2812261$$aRiemenschneider, Henrick$$b0$$udzne
000258264 245__ $$aDataset: Bulk neocortical RNA sequencing of rNLS8 mice (on mixed C57BL/6J × C3H/HeJ background ) +/- active immunization with C-terminal hTDP-43 antigens
000258264 260__ $$bGene Expression Omnibus$$c2023
000258264 3367_ $$2BibTeX$$aMISC
000258264 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1737978339_25504
000258264 3367_ $$026$$2EndNote$$aChart or Table
000258264 3367_ $$2DataCite$$aDataset
000258264 3367_ $$2ORCID$$aDATA_SET
000258264 3367_ $$2DINI$$aResearchData
000258264 520__ $$aThis data set reports RNA sequencing results obtained from whole cerebral cortices of NEFH-tTa/tetO-hTDP43∆NLS transgenic (“rNLS8”) mice that were actively immunized with C-terminal fragments of the human TDP-43 protein. The widely used rNLS8 mouse model overexpresses cytoplasmically mislocalized human TDP-43 in a doxycycline-inducible manner, mimicking ALS/FTD-like CNS pathology and motor dysfunction (Walker et al., 2015). The purpose of this study was to evaluate the safety profile and therapeutic potential of various human TDP-43 epitopes (up to approximately 40 amino acids in length) which were used as antigens for active immunization in a rapidly progressing mouse model of TDP-43 proteinopathy. To this end, we pre-screened 15 peptide antigens, collectively spanning the entire TDP-43 protein sequence, for immunogenicity and safety. Next, we repeatedly immunized “rNLS8” mice with the most promising antigens prior to transgene induction, and performed bulk RNA sequencing of the neocortex, since this region is considerably affected by TDP-43 pathology in both humans and the mouse model. We asked whether active immunization with two different peptide combinations leading to high antibody titers would affect – i.e. prevent – transcriptional alterations upon transgene induction. In summary, we provide a bulk neocortical gene expression profile of actively immunized (and mock-treated) ALS/FTD-resembling “rNLS8” mice.
000258264 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000258264 7001_ $$0P:(DE-2719)2231621$$aEdbauer, Dieter$$b1$$udzne
000258264 8564_ $$uhttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE233669
000258264 909CO $$ooai:pub.dzne.de:258264$$pVDB
000258264 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812261$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000258264 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2231621$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000258264 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000258264 9141_ $$y2023
000258264 9201_ $$0I:(DE-2719)1110004$$kAG Edbauer$$lCell Biology of Neurodegeneration$$x0
000258264 980__ $$adataset
000258264 980__ $$aVDB
000258264 980__ $$aI:(DE-2719)1110004
000258264 980__ $$aUNRESTRICTED